Shawn Allwein, PhD

Vice President, Biologics CMC
Teva Pharmaceuticals

Shawn earned his PhD from the University of Arizona in Synthetic Organic Chemistry followed by an NIH Postdoctoral Fellowship at the University of North Carolina Chapel Hill. He had his initial entry into the pharmaceutical industry within Merck’s small molecule Process Research group before moving Cephalon who was later purchased by Teva Pharmaceuticals. Within small molecule development, Shawn oversaw Teva’s small molecule process development group and internal pilot plant manufacturing of clinical supplies. During this time, he generated over 30 publications in peer reviewed journals.

As part of Teva’s rebranding into the biologics space, Shawn made the move to large molecule research and development with a focus on manufacturing. Initially brought on board to support continuous improvement efforts in manufacturing, Shawn’s role has expanded to Senior Director overseeing Manufacturing and Operations at Teva’s Biologics Manufacturing Facility in West Chester making novel biologics and biosimiliars for Teva’s clinical programs. In 2021, Shawn was promoted to Vice President of Biologics CMC overseeing Drug Substance, Drug Product and Analytical Development along with Manufacturing and Operations within CMC.

Early bird tickets
available now